Effects of OROS methylphenidate (OROS MPH) treatment in children and adolescents with ADHD, mental retardation and epilepsy

被引：1
|
作者：
Kesic, A. [1 ]
Lakic, A. [1 ]
Dronjak, D. [2 ]
Stupar, D. [1 ]
机构：
[1] Sch Med, Inst Neurol & Psychiat Children & Adolescents, Belgrade, Serbia
[2] Gen Hosp, Krusevac, Serbia
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2012年 / 22卷
关键词：
D O I：
10.1016/S0924-977X(12)70659-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S420 / S421
页数：2
相关论文
共 50 条
  • [21] Evaluation of efficacy and safety of OROS® methylphenidate HCl (MPH) extended-release tablets, methylphenidate tid, and placebo in children with ADHD
    Wolraich, ML
    PEDIATRIC RESEARCH, 2000, 47 (04) : 36A - 36A
  • [22] Exploring the Impact of Once-Daily OROS® Methylphenidate (MPH) on Symptoms and Quality of Life in Children and Adolescents with ADHD Transitioning From Immediate-Release MPH
    Kordon, Andreas
    Stollhoff, Kirsten
    Niederkirchner, Kaete
    Mattejat, Fritz
    Rettig, Klaus
    Schaeuble, Barbara
    POSTGRADUATE MEDICINE, 2011, 123 (05) : 27 - 38
  • [23] TRANSITIONING ONTO OROS MPH IS ASSOCIATED WITH IMPROVED FUNCTIONING AND QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS WITH ADHD
    Kordon, A.
    Hultzsch, W.
    Mattejat, F.
    Dichter, S.
    Schaeuble, B.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [24] Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate
    Buitelaar, Jan K.
    Kooij, J. J. Sandra
    Antoni Ramos-Quiroga, J.
    Dejonckheere, Joachim
    Casas, Miguel
    van Oene, Joop C.
    Schauble, Barbara
    Trott, Goetz-Erik
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (02): : 554 - 560
  • [25] Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD
    Kim, Yeni
    Shin, Min-Sup
    Kim, Jae-Won
    Yoo, Hee-Jung
    Cho, Soo-Churl
    Kim, Boong-Nyun
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 (02) : 95 - 102
  • [26] Sustained release methylphenidate (OROS formulation) in therapy of hyperactivity and attention deficit in children with mental retardation
    Lakic, Aneta
    Kesic, Ana
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2011, 20 (01) : S122 - S122
  • [27] Optimizing methylphenidate delivery to improve treatment for ADHD:: Results with OROS® (methylphenidate HCl)
    Lerner, MA
    Modi, NB
    Gupta, S
    PEDIATRIC RESEARCH, 2000, 47 (04) : 29A - 29A
  • [28] Comparison of the impact of OROS methylphenidate HCI with methylphenidate tid and placebo on the sleep of children with ADHD
    Swanson, J
    Sadeh, A
    Lerner, MA
    Wigal, SB
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2000, 21 (05): : 387 - 388
  • [29] Tolerability of OROS-MPH 18 and 36MG in epilepsy plus ADHD
    Gonzalez-Heydrich, J
    Whitney, J
    Hsin, O
    Torres, A
    Mrakotsky, C
    MacMillan, C
    Pravdova, I
    DeMaso, D
    Bourgeois, B
    Biederman, J
    ANNALS OF NEUROLOGY, 2005, 58 : S122 - S122
  • [30] Effect of OROS methylphenidate on encopresis in children with ADHD: a retrospective chart review
    Yilmaz, Savas
    Bilgic, Ayhan
    Herguner, Sabri
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2013, 22 : S216 - S216
12345